Aristeia Capital L.L.C. Takes Position in DaVita Inc. $DVA

Aristeia Capital L.L.C. acquired a new stake in DaVita Inc. (NYSE:DVA) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,896 shares of the company’s stock, valued at approximately $290,000.

Several other hedge funds also recently modified their holdings of DVA. UMB Bank n.a. boosted its position in shares of DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $29,000 after acquiring an additional 76 shares during the period. Copia Wealth Management bought a new stake in shares of DaVita in the fourth quarter valued at approximately $30,000. National Pension Service boosted its position in shares of DaVita by 74.3% in the first quarter. National Pension Service now owns 197 shares of the company’s stock valued at $30,000 after acquiring an additional 84 shares during the period. Y.D. More Investments Ltd bought a new stake in shares of DaVita in the first quarter valued at approximately $35,000. Finally, NewEdge Advisors LLC boosted its position in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after acquiring an additional 88 shares during the period. 90.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on DVA. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research report on Friday, August 22nd. Barclays reduced their target price on DaVita from $169.00 to $160.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Finally, Truist Financial set a $148.00 target price on DaVita in a research report on Friday, August 8th. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, DaVita has an average rating of “Hold” and an average target price of $164.00.

Insider Activity

In other DaVita news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares of the company’s stock, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.50% of the company’s stock.

DaVita Stock Down 2.5%

Shares of DVA stock opened at $134.44 on Tuesday. The stock has a market cap of $9.61 billion, a P/E ratio of 13.22, a price-to-earnings-growth ratio of 0.99 and a beta of 1.13. The stock has a fifty day moving average price of $139.24 and a 200 day moving average price of $141.76. DaVita Inc. has a one year low of $126.07 and a one year high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. The company had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The business’s revenue was up 6.1% on a year-over-year basis. During the same period last year, the business earned $2.00 earnings per share. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.